Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Sunvozertinib approval in China for EGFR Exon 20+ NSCLC by mid-2025?  | Binary | 3 | 2 months ago | ||
Adoption of Novocure's Optune Lua by 50% of US centers for mNSCLC by 2024? | Binary | 2 | 2 months ago | ||
Durvalumab with chemo as standard neoadjuvant treatment for NSCLC in US by 2025? | Binary | 2 | 2 months ago | ||
Leading treatment for mNSCLC in US by market share by end of 2025? | Categorical | 2 | 2 months ago | ||
First region to adopt Optune Lua for mNSCLC post-US approval by end of 2025? | Categorical | 2 | 2 months ago | ||
Leading company in NSCLC treatment innovation by end of 2025? | Categorical | 2 | 2 months ago |